NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that preclinical data on its gene-edited allogeneic CAR T-cells will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29 to June 2, 2015 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that preclinical data on its gene-edited allogeneic CAR T-cells will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29 to June 2, 2015 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
